Journal ArticleDOI
Cancer drug discovery by repurposing: teaching new tricks to old dogs
TLDR
Drugs originally identified as antitussive, sedative, analgesic, antipyretic, antiarthritic, anesthetic, antidiabetic, muscle relaxant, immunosuppressant, antibiotic, antiepileptic, cardioprotective, antihypertensive, erectile function enhancing, or angina relieving are being repurposed for cancer treatment.About:
This article is published in Trends in Pharmacological Sciences.The article was published on 2013-09-01. It has received 303 citations till now. The article focuses on the topics: Repurposing & Drug repositioning.read more
Citations
More filters
Journal ArticleDOI
Metabolic control of YAP and TAZ by the mevalonate pathway
Giovanni Sorrentino,Naomi Ruggeri,Valeria Specchia,Michelangelo Cordenonsi,Miguel Mano,Sirio Dupont,Andrea Manfrin,Eleonora Ingallina,Roberta Sommaggio,Silvano Piazza,Antonio Rosato,Stefano Piccolo,Giannino Del Sal +12 more
TL;DR: It is shown that YAP/TAZ activity is controlled by the SREBP/mevalonate pathway, which is required for proliferation and self-renewal of breast cancer cells and reveals an additional layer of YAP-TAZ regulation by metabolic cues.
Journal ArticleDOI
Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets
TL;DR: LncRNAs are emerging as convenient and minimally invasive diagnostic/prognostic markers, and also as therapeutic target for the selective killing of cancer cells in patients.
Journal ArticleDOI
In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities.
Carlota Rubio-Perez,David Tamborero,Michael P Schroeder,Albert A. Antolin,Jordi Deu-Pons,Christian Perez-Llamas,Jordi Mestres,Abel Gonzalez-Perez,Nuria Lopez-Bigas,Nuria Lopez-Bigas +9 more
TL;DR: A comprehensive assessment of the scope of targeted therapeutic agents in a large pan-cancer cohort and an in silico prescription strategy based on identification of the driver alterations in each tumor and their druggability options is developed.
Journal ArticleDOI
Drug repurposing in cancer.
Linda Sleire,Hilde Elise Førde,Inger Anne Netland,Lina Leiss,Bente Sandvei Skeie,Per Øyvind Enger,Per Øyvind Enger +6 more
TL;DR: An overview of promising candidates for drug repurposing in cancer is provided, as well as studies describing the biological mechanisms underlying their anti-neoplastic effects.
Journal ArticleDOI
Repurposing metformin: an old drug with new tricks in its binding pockets.
Rosina Pryor,Filipe Cabreiro +1 more
TL;DR: The present review provides a thorough and detailed account of the current understanding of the molecular pharmacology and signalling mechanisms underlying biguanide–protein interactions and focuses on the key role of the microbiota in regulating age-associated morbidities and a potential role for metformin to modulate its function.
References
More filters
Journal ArticleDOI
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Steven M. Paul,Daniel S. Mytelka,Dunwiddie Christopher T,Charles C. Persinger,Bernard H. Munos,Stacy R. Lindborg,Aaron Leigh Schacht +6 more
TL;DR: A detailed analysis based on comprehensive, recent, industry-wide data is presented to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity and propose specific strategies that could have the most substantial impact in improving R &D productivity.
Journal ArticleDOI
Antitumor activity of thalidomide in refractory multiple myeloma.
Seema Singhal,Jayesh Mehta,Raman Desikan,D Ayers,Paula K. Roberson,Paul Eddlemon,Nikhil C. Munshi,Elias Anaissie,Carla S. Wilson,Madhav V. Dhodapkar,J Zeddis,Bart Barlogie +11 more
TL;DR: Thalidomide can induce marked and durable responses in some patients with multiple myeloma, including those who relapse after high-dose chemotherapy, and is active against advancedMyeloma.
Journal ArticleDOI
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Gideon Steinbach,Patrick M. Lynch,R. K. S. Phillips,Marina Wallace,Ernest T. Hawk,Gary Gordon,Naoki Wakabayashi,Brian D. Saunders,Yu Shen,Takashi Fujimura,Li Kuo Su,Bernard Levin,Louis Godio,Sherri Patterson,Miguel A. Rodriguez-Bigas,Susan L. Jester,Karen L. King,Marta Schumacher,James L. Abbruzzese,Raymond N. DuBois,Walter N. Hittelman,Stuart O. Zimmerman,Jeffrey W. Sherman,Gary J. Kelloff +23 more
TL;DR: In patients with familial adenomatous polyposis, six months of twice-daily treatment with 400 mg of celecoxib, a cyclooxygenase-2 inhibitor, leads to a significant reduction in the number of colorectal polyps.
Journal ArticleDOI
Thalidomide is an inhibitor of angiogenesis.
TL;DR: Electron microscopic examination of the corneal neovascularization of thalidomide-treated rabbits revealed specific ultrastructural changes similar to those seen in the deformed limb bud vasculature of Thalidomid-treated embryos.
Journal ArticleDOI
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
TL;DR: Characterization of the two COX isozymes is allowing the discrimination of the roles each play in physiological processes such as homeostatic maintenance of the gastrointestinal tract, renal function, blood clotting, embryonic implantation, parturition, pain, and fever.
Related Papers (5)
Drug repositioning: identifying and developing new uses for existing drugs
Ted T. Ashburn,Karl B. Thor +1 more